Clinical Trial Update: The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the combination of all-trans retinoic acid and eltrombopag for steroid-resistant or relapsed immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)
• Vesanoid (all-trans retinoic acid)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Status: COMPLETED